Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 2, randomised, single-blind trial of CL184 in rabies (3 arms), sponsored by Crucell. Primary endpoint: Safety and tolerability at 42 days. Started Mar 2008; status: completed.
02
Design
3 arms- Study design
- RandomizedSingle-blind
CL184 + Vaccine
CL184 (20 IU/kg) on Day 0 + Rabies Vaccine on Days 0, 3, 7, 14, 28
HRIG + Vaccine
HRIG (20 IU/kg) on Day 0 + Rabies Vaccine on Days 0, 3, 7, 14, 28
Placebo + Vaccine
Placebo on Day 0 + Rabies Vaccine on Days 0, 3, 7, 14, 28
03
Who it enrols
Healthy adults aged 19-65 with no prior rabies immunization and no significant health issues.
04
Endpoints
Primary
Safety and tolerability
Secondary
Rabies virus neutralizing activity
Beyond the preview
Go deeper on NCT00656097.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00656097.